CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Vir Biotechnology, Inc. (VIR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Vir Biotechnology, Inc. (VIR)

Biological Products, (No Diagnostic Substances) · market cap $1.9B · as of 2026-11-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
17
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Vir Biotechnology (VIR) is a ~$2.1B market-cap biologics company (~171M shares at ~$12.21, 408 employees) whose lead asset, tobevibart, is listed at Phase 3 for viral hepatitis. Elebsiran is also listed at Phase 3 for viral hepatitis, and the broader pipeline spans chronic hepatitis B, chronic hepatitis D, COVID-19 (sotrovimab, MP0420) and a HER2-expressing oncology program (VIR-5818). The nearest event in our calendar is an estimated 2026-11-15 Phase 2 readout for tobevibart in viral hepatitis (importance 7/10), which follows Q3 earnings on 2026-11-05.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
TobevibartPhase 3Viral Hepatitis
ElebsiranPhase 3Viral Hepatitis
Sotrovimab (Gen1)Phase 2Covid19
VIR-7831 (sotrovimab)Phase 3Covid19
NRTIPhase 2Hepatitis D, Chronic
VIR-2218Phase 2Hepatitis B, Chronic
pegylated interferon-alfa 2aPhase 2Chronic Hepatitis B
VIR-5818Phase 2Locally Advanced or Metastatic HER2-Expressing Cancers
VIR-3434Phase 2Hepatitis B, Chronic
BulevirtidePhase 3Viral Hepatitis
BRII-179Phase 2For Treatment of Chronic Hepatitis B Virus Infection
PEG-IFNαPhase 2Chronic Hepatitis B Virus Infection
Sotrovimab (Gen2)Phase 2Covid19
BRII-835 (VIR-2218)Phase 2For Treatment of Chronic Hepatitis B Virus Infection
SelgantolimodPhase 2Chronic Hepatitis B
BRII-835Phase 2Chronic Hepatitis B Virus Infection
MP0420Phase 3Covid19
Price & technical context
3-month
+6.1%
6-month
+13.3%
12-month
+74.4%
52-wk range
$5.44–$13.65
vs 50-day MA
-10.6%
vs 200-day MA
+2.0%
Realized vol
67.0%
Max drawdown
-65.7%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for VIR (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 17 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.